CV Therapeutics Gets a Boost From Pfizer Study

A study released at the American College of Cardiology in Orlando, Fla., showed that a combination of Norvasc, from Pfizer, and Aceon, co-marketed in the U.S. by Solvay and CV Therapeutics outperformed an older combination of blood-pressure therapies. The study was funded by Pfizer, but CV could also benefit, as Aceon is currently rarely used; sales are in the low tens of millions of dollars. CV is also waiting for news later this year on a new trial of its experimental drug Ranexa, for chronic angina, which may finally get approved. That drug has been caught in regulatory limbo for years.

Forbes (http://www.forbes.com/markets/2005/03/08/0308automarketscan04.html)